Evidence map›Paper›PMID 40299530›Full record

ArticleBiomedicines2025

Efficacy of Durvalumab Consolidation Therapy After Sequential Chemoradiotherapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer-Experience from the Daily Hospital of Clinic for Pulmonology, University Clinical Center of Serbia.

Vesna Ćeriman Krstić, Natalija Samardžić, Spasoje Popević, Ruža Stević, Branislav Ilić, Milija Gajić, Nikola Čolić, Katarina Lukić, Brankica Milošević Maračić, Bojana Poparić Banđur and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Vesna Ćeriman KrstićFaculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-6661-9346
Natalija SamardžićFaculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Spasoje PopevićFaculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-3587-4029
Ruža StevićFaculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0003-3286-3663
Branislav IlićFaculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0001-9350-2461
Milija GajićClinic for Pulmonology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.
Nikola ČolićFaculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0001-6516-1970
Katarina LukićCenter for Radiology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.
Brankica Milošević MaračićInstitute of Oncology and Radiology Serbia, 11000 Belgrade, Serbia.
Bojana Poparić BanđurInstitute of Oncology and Radiology Serbia, 11000 Belgrade, Serbia.
Biljana ŠehaClinic for Neurosurgery, University Clinical Center of Serbia, 11000 Belgrade, Serbia.
Damir RadončićClinic for Pulmonology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.
Jelena Milin LazovićInstitute of Medical Statistics, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-4655-2383

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

durvalumabOSPFSradiotherapyreal-world datastage III NSCLC

Identifiers

PMID40299530
PMCPMC12024546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.